1800 244 735

No surprises in published results from HART study of Huntexil for Huntington's disease

A new paper in the journal Movement Disorders reports the findings of the HART study of pridopidine, also known as Huntexil – a new drug aimed at improving movements in people with Huntington’s disease. Unfortunately this publication doesn’t change much – a new, larger trial is still needed before we will know whether Huntexil works.

Pridopidine, aka Huntexil

Huntexil is an experimental drug which it’s hoped may be beneficial for improving the movement problems experienced by people with Huntington’s disease. It is thought to act by stabilising the behavior of the brain transmitter dopamine. Also known by its chemical name pridopidine, Huntexil was developed by the Danish company NeuroSearch and acquired by Israeli drug giant Teva in 2012. Announced shortly after Dr Michael Hayden took over as Chief Scientific Officer in 2012, the acquisition of Huntexil represented a new commitment to HD research by Teva.

HART

The HART trial precedes Teva’s involvement, and was one of two large trials conducted by NeuroSearch before they sold the drug. HART involved 227 volunteers with Huntington’s disease and was conducted in the USA between 2008 and 2010. The results of the study are fairly well-known since they’ve been announced at various scientific conferences and in press releases, and we’ve written about them here at HDBuzz, too.

The reason Huntexil has raised its head now is that the findings have just been published in the scientific journal Movement Disorders, after a fairly lengthy three-year delay.

Volunteers were given one of three different doses of Huntexil, or a dummy ‘placebo’ tablet, for three months. The drug was safe and well-tolerated, though one patient on a medium dose experienced seizures.

The results were analysed according to a plan that had been set out in advance. That’s important to avoid the pitfall of ‘fishing’ for positive results and only presenting those that happen to be favourable. According to the pre-specified analysis, Huntexil didn’t improve volunteers' movements at any dose. It came close on a couple of ‘secondary’ measures, but essentially the trial was negative.

The broader context

While it’s good that the data from HART are now published, this new paper doesn’t contain any surprises, and it doesn’t change what needs to happen next for Huntexil to get licensed.

HART is one of two large studies of Huntexil carried out by NeuroSearch. Results of the larger study, MermaiHD, were published in 2011 and again, the drug failed to meet the pre-specified level of success to declare the result positive.

When the pooled results of both trials were presented to the European and American regulators, the EMA and the FDA, NeuroSearch was told that it would need to run a third large trial that met the pre-specified tests for success, in order to get a license for the drug. One question was whether the trials had used high enough doses of Huntexil to get the biggest effect.

Teva has announced its intention to “design and complete new clinical studies of Huntexil”, so we can hopefully look forward to an announcement of such a trial in the near future.

Latest Research Articles

Understanding expansions at the single cell level

Published date: 12 March, 2024

In two recent studies, researchers looked at how different parts of the brain are affected by CAG expansions in Huntington’s disease (HD) at the level of individual brain cells. The scientists looked at post-mortem brains from people with and without HD to track molecular changes in different brain regions called the cortex and striatum. These ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 3

Published date: 7 March, 2024

HDBuzz is back for the last day of the CHDI HD Therapeutics Conference: Thursday February 29th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. From genes to medicines The morning session will focus on how human genetics is driving the development of therapeutics. “Genetic modifiers” are genes ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 2

Published date: 6 March, 2024

HDBuzz is back for Day 2 of the CHDI HD Therapeutics Conference: Wednesday February 28th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. It’s a brain disease This morning’s session is titled “It’s a brain disease” and will feature talks about BRAINSSSS! HD scientists are a bit ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 1

Published date: 5 March, 2024

The HDBuzz team recently convened in Palm Springs, California, along with hundreds of other scientists from all over the globe, for the 19th Annual HD Therapeutics Conference, hosted by the HD research foundation CHDI. From Tuesday February 27th through Thursday February 29th, we live-tweeted dozens of scientific talks by world experts in Huntington’s disease research, ... Read more

CRISPR-based drugs: one giant leap for mankind

Published date: 14 February, 2024

You’ve likely heard of CRISPR. By now, you also may have heard that CRISPR has been used to produce a revolutionary new treatment for Sickle Cell Disease. Just 4 years after the Nobel Prize for the discovery of CRISPR was awarded, we have an approved treatment using this technology. This may have you wondering if ... Read more

Making babies: having a family, the HD way

Published date: 11 January, 2024

For people at risk of Huntington’s disease, having a baby who might inherit HD can make decisions around planning a family extremely difficult. This article explains the options available, and how modern reproductive science can make a difference right now to families touched by HD. Content warning This article describes issues of fertility, tough choices, ... Read more